In CRC patients treated with oxaliplatin and capecitabine, senescent fibroblasts exhibiting overexpression of galactosylceramidase (GALC) were observed to promote the tumor progression by up-regulating the transcription factor ATF3 (11). The gene discussed is GALC; the disease is neoplasm.